thalidomide has been researched along with Pyoderma Gangrenosum in 21 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Pyoderma Gangrenosum: An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyoderma gangrenosum has been described in association with multiple myeloma and usually affects patients with active/untreated disease." | 5.42 | Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. ( Alexandrescu, DT; Bockorny, B; Dasanu, CA, 2015) |
| "Thalidomide was introduced, but after complaints of glove and sock paresthesia and hypoesthesia, the drug was discontinued." | 5.38 | Treatment of thalidomide resistant pyoderma gangrenosum with etenercept. ( Baptista, A; Guedes, R; Menezes, N; Moreira, A; Varela, P, 2012) |
| "Thalidomide has been used to treat many inflammatory dermatologic conditions and has been reintroduced in the United States to treat immune-modulated diseases such as pyoderma gangrenosum." | 5.31 | Recalcitrant pyoderma gangrenosum treated with thalidomide. ( Federman, DG; Federman, GL, 2000) |
| "We report successful treatment of a refractory myelodysplastic syndrome-associated pyoderma gangrenosum with the combination of thalidomide and interferon-alpha2a in a single patient." | 3.73 | Successful treatment of myelodysplastic syndrome-induced pyoderma gangrenosum. ( Barista, I; Buyukasik, Y; Calguneri, M; Cetiner, D; Demirhan, B; Duman, AE; Haznedaroglu, IC; Kerimoglu, U; Koca, E; Ozcebe, OI; Uner, A, 2006) |
| "Treatment of pyoderma gangrenosum is often challenging with no standardized treatment protocols." | 1.51 | Case Report: Triple Combination Therapy for Recalcitrant Perineal Pyoderma Gangrenosum ( Cohen, GF; Om, A; Shaath, TS; Wolfe, CM, 2019) |
| "Pyoderma gangrenosum has been described in association with multiple myeloma and usually affects patients with active/untreated disease." | 1.42 | Pyoderma gangrenosum due to lenalidomide use for multiple myeloma. ( Alexandrescu, DT; Bockorny, B; Dasanu, CA, 2015) |
| "Pyoderma gangrenosum is a rare neutrophilic dermatosis that affects 4% of children." | 1.37 | [Pyoderma gangrenosum and Behçet's disease: a study of two pediatric cases]. ( Benchikhi, H; Bouayad, K; Chiheb, S; Hali, F; Khadir, K; Mikou, N, 2011) |
| "Thalidomide has been used to treat many inflammatory dermatologic conditions and has been reintroduced in the United States to treat immune-modulated diseases such as pyoderma gangrenosum." | 1.31 | Recalcitrant pyoderma gangrenosum treated with thalidomide. ( Federman, DG; Federman, GL, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Meunier, M | 1 |
| Larabi, A | 1 |
| Schacherer, M | 1 |
| Deteix, C | 1 |
| Courby, S | 1 |
| Cahn, JY | 1 |
| Vernero, M | 1 |
| Ribaldone, DG | 1 |
| Cariti, C | 1 |
| Ribero, S | 1 |
| Susca, S | 1 |
| Astegiano, M | 1 |
| Dapavo, P | 1 |
| Shaath, TS | 1 |
| Om, A | 1 |
| Wolfe, CM | 1 |
| Cohen, GF | 1 |
| Hu, YQ | 1 |
| Yao, XX | 1 |
| Zhang, JZ | 1 |
| Li, WH | 1 |
| Dasanu, CA | 1 |
| Bockorny, B | 1 |
| Alexandrescu, DT | 1 |
| Cozzani, E | 1 |
| Gasparini, G | 1 |
| Parodi, A | 1 |
| Kim, TH | 1 |
| Oh, SY | 1 |
| Myung, SC | 1 |
| Reddick, CL | 1 |
| Singh, MN | 1 |
| Chalmers, RJ | 1 |
| Hali, F | 1 |
| Khadir, K | 1 |
| Chiheb, S | 1 |
| Bouayad, K | 1 |
| Mikou, N | 1 |
| Benchikhi, H | 1 |
| Guedes, R | 1 |
| Moreira, A | 1 |
| Menezes, N | 1 |
| Baptista, A | 1 |
| Varela, P | 1 |
| Crawford, CL | 1 |
| Meier, F | 1 |
| Berner, D | 1 |
| Scherwitz, C | 1 |
| Rassner, G | 1 |
| Metzler, G | 1 |
| Powell, RJ | 1 |
| Koca, E | 1 |
| Duman, AE | 1 |
| Cetiner, D | 1 |
| Buyukasik, Y | 1 |
| Haznedaroglu, IC | 1 |
| Uner, A | 1 |
| Demirhan, B | 1 |
| Kerimoglu, U | 1 |
| Barista, I | 1 |
| Calguneri, M | 1 |
| Ozcebe, OI | 1 |
| Verrou, E | 1 |
| Kartsios, C | 1 |
| Banti, A | 1 |
| Mihou, D | 1 |
| Kaloutsi, V | 1 |
| Lazaridou, A | 1 |
| Zervas, K | 1 |
| Jacob, SE | 1 |
| Weisman, RS | 1 |
| Kerdel, FA | 1 |
| Costa, I | 1 |
| Castanet, J | 1 |
| Taillan, B | 1 |
| Lacour, JP | 1 |
| Perrin, C | 1 |
| Chazal, M | 1 |
| Mondain, V | 1 |
| Ortonne, JP | 1 |
| Hecker, MS | 1 |
| Lebwohl, MG | 1 |
| Farrell, AM | 1 |
| Black, MM | 1 |
| Bracka, A | 1 |
| Bunker, CB | 1 |
| Federman, GL | 1 |
| Federman, DG | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
3 reviews available for thalidomide and Pyoderma Gangrenosum
| Article | Year |
|---|---|
Pyoderma gangrenosum: a systematic review.
Topics: Anti-Inflammatory Agents; Arthritis; Dermatologic Agents; Diagnosis, Differential; Disease Progressi | 2014 |
Pyoderma gangrenosum of the penis.
Topics: Adult; Anti-Inflammatory Agents; Antitrichomonal Agents; Combined Modality Therapy; Drug Therapy, Co | 1998 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
18 other studies available for thalidomide and Pyoderma Gangrenosum
| Article | Year |
|---|---|
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Substitution; | 2020 |
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Crohn Disease; Drug Therapy, Combination; Humans; Male; Py | 2020 |
Case Report: Triple Combination Therapy for Recalcitrant Perineal Pyoderma Gangrenosum
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Crohn Disease; Cyclosporine; D | 2019 |
Penile pyoderma gangrenosum: Successful treatment with thalidomide.
Topics: Adolescent; Anti-Bacterial Agents; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Male | 2019 |
Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Blood Cell Count; Fatal Outcome; Humans; Knee; Lenalidom | 2015 |
Pyoderma gangranosum of the penis.
Topics: Anti-Inflammatory Agents; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Penile Diseas | 2009 |
Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Com | 2010 |
[Pyoderma gangrenosum and Behçet's disease: a study of two pediatric cases].
Topics: Adolescent; Behcet Syndrome; Child; Dermatologic Agents; Drug Therapy, Combination; Fatal Outcome; F | 2011 |
Treatment of thalidomide resistant pyoderma gangrenosum with etenercept.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Age | 2012 |
The schizophrenic career of a "monster drug".
Topics: Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy; Leprosy, Lepromatous; Nervous System | 2003 |
[An unusual case of pyoderma gangrenosum with necrotizing granulomatous dermatitis].
Topics: Dermatitis; Granuloma; Humans; Male; Middle Aged; Pyoderma Gangrenosum; Rare Diseases; Thalidomide; | 2003 |
Thalidomide. Treat with caution!
Topics: Adult; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Cachexia; Drug Design; Female; Hu | 2006 |
Successful treatment of myelodysplastic syndrome-induced pyoderma gangrenosum.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Myelodysplas | 2006 |
IgG multiple myeloma presented with ulcerative pyoderma gangrenosum.
Topics: Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyoderma Gangrenosum; Thalidomide; Ulcer | 2007 |
Pyoderma gangrenosum--rebel without a cure?
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibo | 2008 |
[Aseptic adenitis in pyoderma gangrenosum].
Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Asepsis; Female; Humans; Lymphadenitis; Pyoderma Gan | 1994 |
Recalcitrant pyoderma gangrenosum: treatment with thalidomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dermatologic Agents; Humans; Male; Middle Aged; Pyoderma Ga | 1998 |
Recalcitrant pyoderma gangrenosum treated with thalidomide.
Topics: Anti-Inflammatory Agents; Dermatologic Agents; Humans; Male; Methylprednisolone; Middle Aged; Pyoder | 2000 |